Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes (Q40758597)

23 September 2017

Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes (English)

1 reference

23 September 2017

0 references

1 reference

Jean-François Gagné

1

1 reference

23 September 2017

André Désormeaux

2

1 reference

23 September 2017

Sylvie Perron

3

1 reference

23 September 2017

Michel J Tremblay

4

1 reference

23 September 2017

Michel G Bergeron

5

1 reference

23 September 2017

language of work or name

1 reference

1 February 2002

1 reference

Biochimica et Biophysica Acta

23 September 2017

1 reference

23 September 2017

1558

1 reference

23 September 2017

2

1 reference

23 September 2017

198-210

1 reference

Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS

23 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

HIV in infected lymph nodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Studies on lymphoid tissue from HIV-infected individuals: implications for the design of therapeutic strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Correlation of virus load in plasma and lymph node tissue in human immunodeficiency virus infection. INCAS Study Group. Italy, Netherlands, Canada, Australia, and (United) States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

HIV-1 and HAART: a time to cure, a time to kill

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Liposomes as drug delivery system: a strategic approach for the treatment of HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution, and pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Lymphoid tissues targeting of liposome-encapsulated 2',3'-dideoxyinosine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Comparison of cellular accumulation, tissue distribution, and anti-HIV activity of free and liposomal 2',3'-dideoxycytidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Long-circulating (sterically stabilized) liposomes for targeted drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Inhibition of human immunodeficiency virus type-1 replication in macrophages and H9 cells by free or liposome-encapsulated L-689,502, an inhibitor of the viral protease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Macrophage-tropic HIV: critical for AIDS pathogenesis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Targeting lymph nodes with liposomes bearing anti-HLA-DR Fab' fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Proteolytic fragmentation with high specificity of mouse immunoglobulin G. Mapping of proteolytic cleavage sites in the hinge region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

The immunopathogenesis of human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Follicular dendritic cells and human immunodeficiency virus infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Human immunodeficiency virus. Trapped but still dangerous

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Cellular Trafficking and Cytotoxicity of Anti-Cd19-Targeted Liposomal Doxorubicin in B Lymphoma Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

Antiviral efficacy, intracellular uptake and pharmacokinetics of free and liposome-encapsulated 2',3'-dideoxyinosine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2',3'-dideoxyinosine

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2801%2900432-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0005-2736(01)00432-1

1 reference

23 September 2017

1 reference